ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Group Opposes Bill To Allow Drug Sales After Phase I.

May 26, 2006

Phase III PANORAMA-1 Trial Meets PFS Primary Endpoint

June 27, 2014

NCI Cooperative Group, Cancer Center Trials Listed

November 28, 2008

Chabner : Opportunity To Set Own Agenda Reason For Leaving

October 28, 1994

Wynder, Weinburg Head Recipients Of Milken Awards

December 14, 1990

NIH Probing: Double Dipping” Allegation

September 4, 1981